In the Real World Study, the Efficacy and Adverse Reactions of Ticagrelor on Ischemic Cerebrovascular Disease
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorQianfoshan Hospital
About this trial
This is a forward-looking, open, one-arm, and real clinical trial world. The researchers plan to recruit at least 50 qualified patients. The main purpose of this study is to establish a population pharmacokinetic model of ticagrelor , explore the correlation between its blood concentration and the events of ischemia and the adverse effects of hemorrhage, and evaluate the effectiveness and safety of ticagrelor in the treatment of ischemic cerebrovascular disease.
Eligibility criteria
Qualifiers
Female or male aged ≥ 18 years.
Clinically diagnosed as ischemic cerebrovascular disease.
Take ticagelor for antiplatelet therapy.
Provision of informed consent.
Disqualifiers
Head CT or MRI suggests the presence of intracranial hemorrhagic disease.
People with tumors and other serious systemic diseases.
Allergy to ticagelor.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
Sponsors and collaborators
Source ClinicalTrials.gov